%PDF-1.4
%
38 0 obj
<>
endobj
35 0 obj
<>
endobj
155 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T16:21:43Z
2024-03-29T04:19:33-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T04:19:33-07:00
application/pdf
Heather
2001-597.july02
uuid:f5270f31-1dd1-11b2-0a00-910927bd7700
uuid:f5270f34-1dd1-11b2-0a00-900000000000
endstream
endobj
24 0 obj
<>
endobj
25 0 obj
<>
endobj
39 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
177 0 obj
[182 0 R]
endobj
178 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.00481 Tw 10 0 0 10 54 713.1616 Tm
(primary SS might probably explain the autoantibody profile)Tj
-0.00011 Tc 0.08791 Tw 0 -1.2 TD
[(detected in our study)65 (, while other diseases such as SLE or)]TJ
0.02499 Tw T*
(SSc were prevalent in other studies)Tj
0 Tc 0 Tw 6.5 0 0 6.5 196.0264 692.4615 Tm
[(2,5,8,10,1)57 (1)]TJ
10 0 0 10 224.9075 689.1616 Tm
(.)Tj
0.14951 Tw -15.8908 -1.2 Td
(Antibodies to Ku protein should be considered a sero-)Tj
0.01151 Tc 0.3634 Tw -1.2 -1.2 Td
(logic marker for overlap syndromes, especially when)Tj
0 Tc 0.3623 Tw T*
(myositis is present; anti-Ku are frequently detected in )Tj
0.2962 Tw T*
(association with other antinuclear specificities including)Tj
-0.00011 Tc 0.02499 Tw T*
(other markers of overlap syndromes.)Tj
/TT1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 61 595.1616 Tm
[(1.)-875 (Mimori )18 (T)74 (, )55 (Akizuki M, )37 (Y)100 (amagata H, Inada S, )37 (Y)100 (oshida S, Homma M.)]TJ
1.675 -1.25 Td
(Characterization of a high molecular weight acid nuclear protein)Tj
0 -1.25 TD
(recognized by autoantibodies in sera from patients with)Tj
T*
[(polymyositis-scleroderma overlap. J Clin Invest 1981;68:61)37 (1-20. )]TJ
-1.675 -1.25 Td
[(2.)-875 (Reeves )18 (WH. Use of monoclonal antibodies for the characterization)]TJ
1.675 -1.25 Td
(of novel DNA-binding proteins recognized by human autoimmune)Tj
T*
(sera. J Exp Med 1985;161:18-39.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875 (Y)100 (aneva M, Ochs R, McRorie DK, Zweig S, Busch H. Purification)]TJ
0 Tc 1.675 -1.25 Td
(of an 86-70 kDa nuclear DNA-associated protein complex.)Tj
T*
[(Biochim Biophys )55 (Acta 1989;841:22-9.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875 (Mimori )18 (T)74 (, Hardin JA, Steitz JA. Characterization of the )]TJ
0 Tc 1.675 -1.25 Td
(DNA-binding protein antigen Ku recognized by autoantibodies)Tj
T*
(from patients with rheumatic disorders. J Biol Chem)Tj
0 Tw T*
(1986;261:2274-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875 (Y)100 (aneva M, )55 (Arnett FC. )55 (Antibodies against Ku protein in sera from)]TJ
0 Tc 1.675 -1.25 Td
(patients with autoimmune diseases. Clin Exp Immunol)Tj
0 Tw T*
(1989;76:366-72.)Tj
0.0249 Tw -1.675 -1.25 Td
[(6.)-875 (Chan JY)129 (, Lerman MI, Prabhakar BS, et al. Cloning and )]TJ
1.675 -1.25 Td
[(characterization of a cDNA)-220 (that encodes a 70-kD novel human)]TJ
T*
(thyroid autoantigen. J Biol Chem 1989;264:3651-4.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875 (Isern )55 (AR, )37 (Y)100 (aneva M, Parke )55 (A, Rothfield N, Dantzker D, Rich S.)]TJ
0 Tc 1.675 -1.25 Td
(Autoantibodies in patients with primary pulmonary hypertension:)Tj
T*
[(association with anti-Ku. )55 (Am J Med 1992;93:307-12.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875 (Cooley HM, Melny BJ, Gleeson R, Greco )18 (T)74 (, Kay )18 (TWH. Clinical)]TJ
0 Tc 1.675 -1.25 Td
[(and serological associations of anti-Ku antibody)65 (. J Rheumatol)]TJ
0 Tw T*
(1999;26:563-7.)Tj
0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Satoh M, Langdon JJ, Reeves )18 (WH. Clinical application of an )]TJ
-0.00011 Tc 1.675 -1.25 Td
(anti-Ku antigen-capture ELISA. Clin Immunol Newsletter)Tj
0 Tc 0 Tw T*
(1993;13:23-31.)Tj
0.0249 Tw -2.175 -1.25 Td
[(10.)-875 (Reeves )18 (WH, Pierani )55 (A, Chou C-H, et al. Epitopes of the p70 and)]TJ
2.175 -1.25 Td
(p80 \(Ku\) lupus autoantigens. J Immunol 1991;146:2678-86.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Reeves )18 (WH, Satoh M, Stojanov L, )18 (W)80 (ang J. Ku and Ki )]TJ
2.1381 -1.25 Td
[(autoantibodies. In: Peter JB, Shoenfeld )37 (Y)129 (, editors. )55 (Autoantibodies.)]TJ
T*
(Amsterdam: Elsevier Science; 1996:449-55.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875 (W)80 (ang J, Shaw M, Stojanov L, Har)18 (graves J, Satoh M, Reeves )18 (WH.)]TJ
0 Tc 2.175 -1.25 Td
[(High frequency of anti-Ku autoantibodies in )55 (African-American)]TJ
T*
[(SLE patients [abstract]. )55 (Arthritis Rheum 1998;41 Suppl:236.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875 (Francoeur )55 (AM, Peebles CL, Gompper PT)74 (, )18 (T)70 (an EM. Identification of)]TJ
0 Tc 2.175 -1.25 Td
(Ki \(Ku, p70/p80\) autoantigens and analysis of anti-Ki autoantibody)Tj
T*
[(reactivity)65 (. J Immunol 1986;136:1648-53.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875 (T)70 (an EM, Cohen )55 (AM, Fries JF)80 (, et al. )18 (The 1982 revised criteria for)]TJ
0 Tc 2.175 -1.25 Td
[(the classification of systemic lupus erythematosus. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw 30.825 67.421 Td
[(15.)-875 (Masi )55 (A)111 (T)74 (, Rodnan GP)111 (, Medsger )18 (T)80 (A)-220 (Jr)40 (, et al. Preliminary criteria for)]TJ
2.175 -1.25 Td
[(the classification of systemic sclerosis \(scleroderma\). )55 (Arthritis)]TJ
0 Tc T*
(Rheum 1980;23:581-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875 (Bohan )55 (A, Peter JB. Polymyositis and dermatomyositis. N Engl J)]TJ
0 Tc 2.175 -1.25 Td
(Med 1965;292:344-7.)Tj
-2.175 -1.25 Td
[(17.)-875 (V)60 (itali C, Bombardieri S, Moutsopoulos HM, et al. )55 (Assessment of)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(European classification criteria for Sj\366gren\222)55 (s syndrome in a series)]TJ
0 Tc T*
(of clinically defined cases: results of a prospective multicentre)Tj
T*
[(study)65 (. )55 (Ann Rheum Dis 1996;55:1)37 (16-21.)]TJ
-2.175 -1.25 Td
[(18.)-875 (Harris EN. )18 (The second international anticardiolipin standardization)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(workshop/The Kingston )55 (Antiphospholipid )55 (Antibody Study \(KAPS\))]TJ
0 Tc T*
[(Group. )55 (Am J Clin Pathol 1990;94:476-84.)]TJ
-2.175 -1.25 Td
[(19.)-875 (Bernstein RM, Bunn CC, Hughes GR)80 (V)129 (. Identification of antibody)]TJ
2.175 -1.25 Td
[(to acidic antigens by counterimmunoelectrophoresis. )55 (Ann Rheum)]TJ
T*
(Dis 1982;41:554-5.)Tj
-2.175 -1.25 Td
[(20.)-875 (Clark G, Reichlin M, )18 (T)70 (omasi )18 (TB. Characterization of a soluble)]TJ
2.175 -1.25 Td
(cytoplasmic antigen reactive with sera from patients with systemic)Tj
T*
[(lupus erythematosus. J Immunol 1969;102:1)37 (17-22.)]TJ
-2.175 -1.25 Td
[(21.)-875 (V)111 (enables PJW)92 (, Smith PR, Maini RN. Purification and )]TJ
2.175 -1.25 Td
[(characterization of the Sj\366gren\222)55 (s syndrome )55 (A)-220 (and B antigens. Clin)]TJ
T*
(Exp Immunol 1983;54:731-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875 (Moll JMH, )18 (W)40 (right )18 (V)129 (. Psoriatic arthritis. Semin )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1973;3:55-78.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875 (Mosca M, Neri R, Bombardieri S. Undif)18 (ferentiated connective)]TJ
2.175 -1.25 Td
(tissue diseases: a review of the literature and a proposal for )Tj
0 Tc T*
(preliminary classification criteria. Clin Exp Rheumatol)Tj
0 Tw T*
(1999;17:615-20.)Tj
0.0249 Tw -2.175 -1.25 Td
[(24.)-875 (Bernstein RM, Mor)18 (gan SH, Bunn CC, Gainey RC, Hughes GR)80 (V)129 (,)]TJ
2.175 -1.25 Td
[(Mathews MB. )18 (The SL)-238 (autoantibody-antigen system: clinical and)]TJ
T*
[(biochemical studies. )55 (Ann Rheum Dis 1986;45:353-8.)]TJ
-2.175 -1.25 Td
[(25.)-875 (Parodi )55 (A, Rebora )55 (A. )55 (Anti-Ku autoantibodies in connective tissue)]TJ
-0.02991 Tw 2.175 -1.25 Td
[(diseases. )-55 (J Am Acad )-55 (Dermatol )-55 (1989;21:433-5.)]TJ
0.0249 Tw -2.175 -1.25 Td
[(26.)-1000 (Y)100 (amanishi )37 (Y)129 (, Maeda H, Katayama S, Ishioka S, )37 (Y)100 (amakido M.)]TJ
-0.00011 Tc 2.25 -1.25 Td
(Scleroderma-polymyositis overlap syndrome associated with )Tj
0 Tc T*
(anti-Ku antibody and rimmed vacuole formation. J Rheumatol)Tj
0 Tw T*
(1996;23:1991-4.)Tj
-0.00011 Tc 0.02499 Tw -2.25 -1.25 Td
[(27.)-875 (Parodi )55 (A, Puiatti P)111 (, Rebora )55 (A. Serological profiles as prognostic)]TJ
2.175 -1.25 Td
(clues for progressive systemic scleroderma: the Italian experience.)Tj
0 Tc T*
(Dermatologica 1991;183:15-20.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875 (Limbach F-X, Goetz J, Javier R-M, Kuntz J-L, Sibilia J. Clinical)]TJ
0 Tc 2.175 -1.25 Td
[(significance of anti-Ku antibody [abstract]. )55 (Arthritis Rheum)]TJ
T*
(2000;43 Suppl:1879.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875 (Boire G, Menard H-A. Detection of antibodies to SS-A/Ro antigen)]TJ
0 Tc 2.175 -1.25 Td
[([reply]. )55 (Arthritis Rheum 1992;35:1)37 (109-12.)]TJ
-2.175 -1.25 Td
[(30.)-875 (Reichlin M. )55 (Antibodies to ribonuclear proteins. Rheum Dis Clin)]TJ
-0.02991 Tw 2.175 -1.25 Td
[(North Am )-55 (1994;20:29-43.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(31.)-875 (Abu-Elheiga L, )37 (Y)100 (aneva M. )55 (Antigenic determinant of the 70-kDa)]TJ
2.175 -1.25 Td
(subunit of the Ku autoantigen. Clin Immunol Immunopathol)Tj
0 Tw T*
(1992;64:145-52.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875 (Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW)92 (, et al.)]TJ
0 Tc 2.175 -1.25 Td
(Clinical, serologic, and immunogenetic features in Polish patients)Tj
T*
[(with idiopathic inflammatory myopathies. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1997;40:1257-66.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Franceschini, et al: )18 (Anti-Ku antibodies)]TJ
0 Tw 60.9375 -0.0313 Td
(1397)Tj
ET
0 0 0 0 scn
/GS0 gs
101.14 57.14 407.5 -10.83 re
f*
0.5 w
101.14 57.14 407.5 -10.83 re
S
Q
Q
q
1 0 0 1 0 -2 cm
0 0 612 792 re
W n
1 0 0 1 0 2 cm
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 49 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
80 0 obj
<>
endobj
161 0 obj
<>
endobj
47 0 obj
<>
endobj
53 0 obj
<>
endobj
41 0 obj
<>
endobj
43 0 obj
<>
endobj
75 0 obj
<>stream
HVPTι"bzW6@_YUS_hD_$"*C4cuhj4ڱ JXa;LuT1Fw|%3?g@;@AW{6L
y([\ᯌ;@/\MW6rf(M<xϖKv\mjf, ∖N{yEՂ=ߐ a)#s`J9_WuwxUΙ_e-y;^9p2!JZQGJ֭`2Z_+ C+<.b=`s)*}1(AOHlrAF`=vi/6"T?ٴ++S8 !YgF/bXkEdocnfFbՌiĵiDAϝE*q/*l"8'*ʱY'^?(ke])N%̽^c)
|'lƝ?q
$f]GY2_N
<%ȯ5yS+5>P՝Z6C[ho'MӊRjkj`WU2IeWGc,G.O4e,`57G>Y:NqxPY<)73&